参考文献

参考文献

  1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55(2):74-108.
  2. McGowan L, Lesher LP, Norris HJ, Barnett M. Misstaging of ovarian cancer. Obstet Gynecol 1985;65(4):568-72.
  3. Guidelines for referral to a gynecologic oncologist: rationale and benefits. The Society of Gynecologic Oncologists. Gynecol Oncol. 2000;78(3 Pt 2):S1-S13.
  4. Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 2000. CA Cancer J Clin. 2000;50(1):7-33.
  5. American College of Obstetricians and Gynecologists. ACOG Committee Opinion: number 280, December 2002. The role of the generalist obstetrician-gynecologist in the early detection of ovarian cancer. Obstet Gynecol. 2002;100(6):1413-1416.
  6. Ovarian Cancer National Alliance. Ovarian cancer statistics. www.ovariancancer.org/index.cfm?fuseaction=Page.viewPage&PageID=765&CFID=15118410&CFTOKEN=8494f3583d9110a0-
    7A4B5C4C-15C5-E1E2-3EB538F2D225A65C    . Accessed March 4, 2008.
  7. Ovarian Cancer National Alliance. Types of ovarian cancer. www.ovariancancer.org/index.cfm?fuseaction=Page.viewPage&PageID=772&CFID=15118410&CFTOKEN=8494f3583d9110a0-
    7A4B5C4C-15C5-E1E2-3EB538F2D225A65C#types    . Accessed March 4, 2008.
  8. Ovarian Cancer National Alliance. Risk factors. www.ovariancancer.org/index.cfm?fuseaction=Page.viewPage&PageID=766&CFID=15118410&CFTOKEN=8494f3583d9110a0-
    7A4B5C4C-15C5-E1E2-3EB538F2D225A65C    . Accessed March 4, 2008.
  9. Moore RG, Brown AK, Miller CM, et al. The use of multiple novel serum tumor markers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol. 2008;108(2):402-408.
  10. CA125II™ Radioimmunoassay [Product insert], Fujirebio Diagnostics, Inc.
  11. Ovarian Cancer National Alliance. Seeking the care of a gynecologic oncologist. www.ovariancancer.org/index.cfm?fuseaction=Page.viewPage&PageID=772&CFID=15118410&CFTOKEN=8494f3583d9110a0-
    7A4B5C4C-15C5-E1E2-3EB538F2D225A65C#seeking    . Accessed March 4, 2008.
  12. Moore RG, Bast RC Jr. How do you distinguish a malignant pelvic mass from a benign pelvic mass? Imaging, biomarkers, or none of the above. J Clin Oncol. 2007;25(27):4159-4161.
  13. NIH consensus conference. Ovarian cancer. Screening, treatment, and follow-up. NIH Consensus Development Panel on Ovarian Cancer. JAMA. 1995;273(6):491-497.
  14. National Comprehensive Cancer Network. NCCN practice guidelines in oncology—v.1.2006. www.nccn.org/professionals/physician_gls/PDF/ovarian.pdf. Accessed March 3, 2008.
  15. Knapp RC, Jacobs I, Schwartz, P. Clinical perspectives on the use of the CA125 radioimmunoassay in ovarian cancer. Contemp Ob Gyn. 1996;41:99.
  16. Ovarian Cancer National Alliance. Early detection. www.ovariancancer.org/index.cfm?fuseaction=Page.viewPage&pageId=771&parentID=764&nodeID=1. Accessed March 4, 2008.
  17. Benedet JL, Bender H, Jones H 3rd, Ngan HY, Pecorelli S. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int J Gynecol Obstet. 2000;70(2):209-262.
  18. American Cancer Society. What are the key statistics about ovarian cancer? www.cancer.org/docroot/CRI/content/CRI_2_4_1X_What_are_the_key_statistics_for_ovarian_cancer_33.asp?sitearea=. Accessed March 4, 2008.
  19. HE4 EIA [Package insert], Fujirebio Diagnostics, Inc.
  20. Data on File [Pelvic mass algorithm report], Fujirebio Diagnostics, Inc.
  21. Kenemans P, van Kamp GJ, Oehr P, Verstraeten RA. Heterologous double-determinant immunoradiometric assay CA125II: reliable second-generation immunoassay for determining CA125 in serum. Clin Chem. 1993;39(12):2509-2513.
  22. Data on File [Clinical Data Report], Fujirebio Diagnostics, Inc.